Agios Pharmaceuticals (NASDAQ:AGIO) Shares Up 5.2% – Should You Buy?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) traded up 5.2% on Monday . The stock traded as high as $40.99 and last traded at $40.99. 84,013 shares were traded during mid-day trading, a decline of 88% from the average session volume of 714,662 shares. The stock had previously closed at $38.97.

Wall Street Analyst Weigh In

AGIO has been the subject of a number of research reports. Leerink Partners lowered shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $60.00 to $56.00 in a report on Friday, September 27th. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Leerink Partnrs downgraded shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Scotiabank boosted their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $56.33.

Agios Pharmaceuticals Stock Down 1.7 %

The firm has a market capitalization of $2.39 billion, a price-to-earnings ratio of 3.69 and a beta of 0.80. The company has a fifty day moving average price of $50.09 and a two-hundred day moving average price of $46.84.

Insiders Place Their Bets

In other news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the transaction, the chief financial officer now owns 20,158 shares of the company’s stock, valued at $988,346.74. The trade was a 11.20 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 4.93% of the stock is owned by insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp raised its holdings in shares of Agios Pharmaceuticals by 10.2% in the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after acquiring an additional 216,484 shares during the last quarter. D. E. Shaw & Co. Inc. raised its stake in Agios Pharmaceuticals by 87.3% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 678,234 shares of the biopharmaceutical company’s stock valued at $29,245,000 after purchasing an additional 316,100 shares during the last quarter. Vestal Point Capital LP purchased a new position in Agios Pharmaceuticals in the 3rd quarter valued at about $33,767,000. Seven Eight Capital LP acquired a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth about $1,693,000. Finally, Edgestream Partners L.P. purchased a new stake in shares of Agios Pharmaceuticals during the second quarter worth about $1,814,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.